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Onchocerciasis and 
Mectizan
Mectizan® has been donated for the 
control of onchocerciasis for over twenty 
years, and also for the elimination of 
lymphatic filariasis for the last ten years. 
Merck & Co. Inc, or MSD as the company 
is known in many other parts of the world, 
are donating Mectizan® to as many who 
need it for as long as it is needed. But 
how much is needed? Individual patients 
with skin disease or eye disease need 
only small amounts, but where the preva-
lence of skin disease or eye disease in an 
area is high it is important to treat all 
eligible people in the community. If we 
treat around 65% of the population on a 
regular basis, the effects of the disease 
will be drastically reduced. If however we 
maintain 80% coverage of the total 
population (or 95–100% of the eligible 
population) onchocerciasis may 
eventually be eliminated. Mectizan® is 
usually given annually. In some areas, 
where it is feasible, treatment takes place 
twice and even four times a year to break 
the transmission cycle more quickly. That 
amounts to a lot of tablets!
What information is 
needed?
In order to supply the correct amount of 
Mectizan®, we need data on the total 
population and/or the eligible population 
planned for treatment, the expected 
coverage level, and the planned number 
of treatment rounds during the year. The 
amount of Mectizan® needed can then be 
calculated. However, if the treatment 
planned was not completed the previous 
year, the amount has to 
be adjusted in order to 
avoid accumulating 
potentially expired 
drugs. It takes time to 
manufacture and ship 
drugs, and we need to 
know how much to 
produce in order to 
ensure that enough 
Mectizan® will be 
available when required. Prompt reporting 
of treatment, or even of difficulties in 
distribution, help to resolve some of these 
problems before they negatively impact 
drug delivery. 
The programme’s major partner for 
distribution is the African Programme for 
Onchocerciasis Control (APOC). APOC 
has developed the strategy of community-
directed treatment with ivermectin (CDTI). 
The communities, once sensitised, take 
ownership of the 
programme and run it 
themselves, including 
choosing community 
distributors and organ-
ising community 
supervision. For this to 
work, there has to be a 
close relationship with 
the most peripheral 
elements of the primary 
health care system, usually the health 
centre staff. We therefore also need infor-
mation about how staff involved in 
onchocerciasis control are trained and 
functioning at all levels of the health 
service, and how many people need to be 
trained or retrained. This information is 
vital for planning and budgetary purposes, 
especially if other interventions are 
needed or if strategies change.
How is the information 
collected?
Information is collected at different levels. 
At the community level, the community 
distributors are responsible for the 
collection of local treatment information, 
which is collected and collated (summa-
rised) by the health centre nurse for the 
whole health area (the area supervised by a 
health centre). The nurse will add data on 
training, tablet inventory, etc. and send a 
report to the health district. The health 
district will add data on training, supervision, 
and other activities at the district level.
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Community distributors are responsible for the collection of local treatment data. 
BurunDi
‘It takes time to 
manufacture and 
ship drugs, and we 
need to know how 
much to produce’
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We have just passed the halfway mark for 
the VISION 2020 global initiative, which 
was launched in 1999 with the goal to 
eliminate avoidable blindness by the year 
2020. This is a good time to take stock of 
what we have achieved and what still 
needs to be done.
The success of VISION 2020 has to be 
judged against its impact on reducing 
levels of avoidable blindness in the world. 
Although still to be finally approved by 
WHO, some preliminary data on the global 
prevalence of blindness and visual 
impairment was presented in a meeting 
between WHO and IAPB members in 
October 2010. It suggests a decline of 
approximately 10% in the overall number 
of blind and visually impaired. Compared 
to the 314 million people with visual 
impairment (≤6/18) from WHO data 
produced in 2004, the new figures 
suggest a total of 285 million. Overall, 
this is a decrease of nearly 29 million. 
The number of blind people (≤3/60, 
presenting vision) has fallen from an 
estimated 45 million to 39.8 million. If 
these figures are confirmed, and if we 
take into account that, over the same 
period, there has been an 18% increase 
in the population of those aged 50 years 
and older worldwide, then we have some 
cause for optimism.
We also know that: 
• The prevalence of blindness is decreasing 
in some countries that have adopted 
VISION 2020 strategies. The most 
recent national studies done in 
Pakistan, India, and The Gambia 
have all shown significant declines 
in prevalence rates compared to 
earlier surveys.
• The number of cataract operations 
done in India has increased fivefold over 
the past 25 years, to more than 5 million 
per year, and the lessons learnt are 
having a major positive impact in 
other countries.
• Blindness due to trachoma and 
onchocerciasis has decreased 
significantly and the possibility of the 
elimination of transmission of these 
two diseases by the year 2020 is 
within reach.
• Childhood blindness is decreasing due 
Normally, data is further centralised at 
the provincial level before being passed to 
the central level where it is forwarded to 
the supporting programmes and the drug 
donation programme. There has been an 
effort to get treatment data integrated 
into existing health management infor-
mation systems in countries, but this has 
been a slow process, and there are many 
discussions about which indicators to 
use. As health systems are often weak at 
the periphery (e.g. remote or rural areas), 
community data may be collected by a 
supporting non-governmental organisation 
(NGO) in a parallel way and then 
forwarded to the government for their 
reports. Mectizan® is often donated 
through NGOs, so they are an important 
part of the process. 
People need to be trained at the 
respective levels in order to collect this 
vital information. Once chosen by their 
community, distributors are trained in a 
very practical way, as close as possible to 
their community. Treatment is usually 
written down for each individual, and by 
family, in a locally bought exercise book or 
in specially printed registers. In some 
remote communities, volunteers may be 
illiterate. However, even in these circum-
stances, volunteers can be trained to use 
a simple tally sheet, which is often used 
to summarise data in any case. Training 
at the community level is usually done by 
the health centre staff who are in turn 
trained by staff at the district level, who 
have received their training at a provincial 
level. This form of ‘cascade’ training is a 
very effective process, but care must be 
taken to make sure the essential 
messages are relayed correctly at the 
relevant levels. Close supervision is required 
as incorrect data leads to incorrect tablet 
data or information for planning. 
During the distribution process, the 
distributors are often helped by other 
volunteers to enter data into the exercise 
book or register. Having one page per 
household makes it easier to locate 
individuals for follow-up of the annual 
treatment or to find people who were 
absent at the time of treatment.
The treatment summaries are 
prepared at the community level. These 
show numbers treated by gender and 
sometimes by dose (1–4 tablets) and 
also reasons for not taking the tablets 
(too young, pregnant, too ill, absent from 
the village, etc.). The health area nurse 
then collects data from all the commu-
nities and forwards it to the health district 
where it is centralised, sometimes 
computerised, and then forwarded to 
higher levels with their own activity report. 
Once again, NGOs sometimes facilitate 
this process.
How is the information 
analysed and used?
The data collected by the volunteers are 
usually analysed at the community level 
and the following are calculated: total 
number of people treated, number of 
tablets used, and sometimes coverage 
(percentage or proportion of population 
treated). Volunteers may also use the 
family treatment sheets to follow up on 
those who had not received treatment, 
often revisiting their homes. They may 
also try to follow up on people refusing 
treatment. Specially trained community 
volunteers may also participate in this 
analysis and may calculate the coverage. 
Health centre nurses usually discuss the 
results with community volunteers and 
will check the coverage levels. At the 
district level, health centres are compared 
and the results are tabulated and 
coverage calculated before the report is 
forwarded to the provincial or central level.
The information is used in different 
ways at different levels: 
• At the community level, the details of 
treatment are shared and the coverage 
is discussed with the community 
distributors, including the importance of 
high coverage for control or elimination. 
Problems or low coverage are discussed 
to try and resolve challenges. 
Sometimes, coverage is compared 
between communities to see “who is 
doing best.” 
• At the health centre level, coverage is 
calculated: people responsible for high 
coverage are congratulated; 
discussions are held with those with low 
coverage and solutions examined. At 
this time, strategies for the next 
treatment round will be discussed and 
the needs for tablets will be calculated. 
• At the district level, coverage is again 
the main issue as well as planning and 
budgeting for the next treatment round 
(training, retraining, further health 
education, etc.). 
• At the central (national) level, the 
reports are used to calculate the next 
year’s tablet request.
VISION 2020
Ten years to VISION 2020: how are we doing?
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Community distributors can use the data 
they collect to do a follow-up. BurunDi
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